Uncategorized

GSK prepares for patent cliff with $2.5B cost-cutting plan

Published

on

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version